David Borges Sells 10,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 10,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,906 shares of the company’s stock, valued at approximately $111,918.70. The trade was a 62.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Trading Down 5.5%

NASDAQ:OMER opened at $18.22 on Thursday. The stock has a market capitalization of $1.32 billion, a PE ratio of 14.23 and a beta of 2.54. Omeros Corporation has a 1-year low of $3.94 and a 1-year high of $19.65. The firm has a fifty day simple moving average of $12.30 and a 200 day simple moving average of $11.92.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. On average, equities analysts predict that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC increased its stake in shares of Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares during the period. Farther Finance Advisors LLC boosted its stake in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,004 shares during the period. State of Wyoming bought a new stake in Omeros in the 4th quarter valued at $25,000. AQR Capital Management LLC grew its holdings in Omeros by 7.2% in the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 1,532 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 1,637 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

OMER has been the subject of several recent analyst reports. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Finally, Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.